The stock of Baxalta (NYSE:BXLT) registered a decrease of 2.29% in short interest. BXLT’s total short interest was 7.71M shares in February as published by FINRA. Its down 2.29% from 7.89 million shares, reported previously. With 11.56 million shares average volume, it will take short sellers 1 days to cover their BXLT’s short positions. The stock is down 0.63% or $0.25 after the news, hitting $39.27 per share. About 2.32M shares traded hands. Baxalta Inc (NYSE:BXLT) has risen 20.92% since July 17, 2015 and is uptrending. It has outperformed by 29.44% the S&P500.
Baxalta Incorporated is a biopharmaceutical company. The company has a market cap of $26.76 billion. The Firm develops, makes and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions. It has 28.81 P/E ratio. The Firm also focuses on disease areas, including oncology, as well as technology platforms, including gene therapy and biosimilars.
Out of 2 analysts covering Baxalta (NYSE:BXLT), 3 rate it “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Baxalta was the topic in 4 analyst reports since August 10, 2015 according to StockzIntelligence Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.